• DOI:10.1007/s40259-017-0248-z
Corpus ID: 9282946

Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology

@article{Pardridge2017DeliveryOB,
  title={Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology},
  author={W. Pardridge},
  journal={BioDrugs},
  year={2017},
  volume={31},
  pages={503-519}
}

W. Pardridge

Published 2017

Medicine

BioDrugs

Biologics are potential new therapeutics for many diseases of the central nervous system. Biologics include recombinant lysosomal enzymes, neurotrophins, decoy receptors, and therapeutic antibodies. These are large molecule drugs that do not cross the blood–brain barrier (BBB). All classes of biologics have been tested, without success, in clinical trials of brain disease over the last 25 years. In none of these past clinical trials was the biologic re-engineered to enable transport across the… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed